STAT
MAY 31, 2023
“Hey, I’m sorry to bother you, but I could really use your advice on something.” As fellows in oncology training programs, we’re both accustomed to fielding texts, emails, and calls that start out like the above from family, friends, and acquaintances seeking guidance for themselves or their loved ones after a cancer diagnosis.
PharmaVoice
MAY 31, 2023
With the recent approval of Krazati, the biotech veteran is guiding Mirati into its next phase as a commercial-based organization.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MAY 31, 2023
As Congress considers wide-ranging reforms to pharmacy benefit managers, a top executive at CVS Health, which owns one of the largest PBMs in the country, said the company would find ways to maintain its level of profit if those reforms to things like drug rebates went into effect. “There’s other ways in the economic model that we can adjust to if one of those things changes,” Shawn Guertin, CVS’ chief financial officer, said at an industry conference Wednesday.
PharmaVoice
MAY 31, 2023
As lawmakers shine a light on Big Pharma tax cuts, the industry’s business moves are coming under attack from multiple angles.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
MAY 31, 2023
The Food and Drug Administration approved a second vaccine to protect older adults against RSV on Wednesday, giving a green light to Pfizer’s Abrysvo for adults 60 and older. Early in May the FDA approved the first ever vaccine against respiratory syncytial virus, or RSV, when it licensed GSK’s Arexvy.
BioPharma Dive
MAY 31, 2023
The biotech, best known for its success developing migraine medicines, will seek approval of a treatment that failed a Phase 3 trial but showed signs of a positive effect.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharmaceutical Technology
MAY 31, 2023
XtalPi has made a partnership deal with US-based Eli Lilly to leverage artificial intelligence (AI) for drug discovery. XtalPi will receive $250m in upfront and milestone payments. The two companies will use XtalPi’s integrated AI capabilities and robotics platform for the de novo [without consideration of previous instances] design and delivery of drug candidates for an undisclosed target.
STAT
MAY 31, 2023
Hey there. STAT reporter Andrew Joseph here welcoming you to Wednesday’s edition of Pharmalittle, with Pharmalot himself off for the day. We’re based here in London, so instead of firing up another cup of stimulation, we’re more focused on what post-lunch snack awaits us. As we ponder, we’ll leave you with the latest headlines.
BioPharma Dive
MAY 31, 2023
The company’s experimental treatment for myotonic dystrophy became the latest neuromuscular disease therapy to face a regulatory roadblock before the start of human testing.
Pharmaceutical Business Review
MAY 31, 2023
The fundraise saw the participation of new and existing investors Kineticos Ventures and MVM Partners , respectively. Kineticos Ventures president and CEO Frank Lis is joining eXmoor board as a result of the financing. The investment will allow eXmoor to launch its Cell and Gene Therapy Centre, a 65,000ft 2 good manufacturing practice (GMP) facility.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
BioPharma Dive
MAY 31, 2023
The shot’s clearance comes several weeks after the regulator made GSK’s Arexvy the first vaccine for RSV in the U.S.
The Pharmacist
MAY 31, 2023
The deputy chief pharmaceutical officer (CPhO) for NHS England, Dr Bruce Warner, has retired today. Colleagues within the sector have thanked him for his work, including for championing the clinical role of community pharmacy and integrating pharmacists and pharmacy technicians within GP practices. Dr Warner has been the deputy CPhO since 2014, having previously worked […] The post Dr Bruce Warner retires as deputy CPhO appeared first on The Pharmacist.
European Pharmaceutical Review
MAY 31, 2023
The inventory position of 28 major pharmaceutical manufacturers in 2022 has been revealed in an annual report. Analysis explored the impact of macro-trends on inventory management from corporate reports of Big Pharma companies including Merck, AstraZeneca and Pfizer. It investigated how excessive inventories are affecting the industry and what factors could influence inventory growth in 2023.
The Pharmacist
MAY 31, 2023
The Royal Pharmaceutical Society (RPS) and the Pharmacists’ Defence Association (PDA) have joined nearly 40 organisations to call on the government to publish the long-awaited NHS workforce plan. The plan is set to put forward solutions to address NHS understaffing and was expected to be published imminently, but has been rumoured to be delayed due […] The post Pharmacy bodies join call for publication of NHS workforce plan appeared first on The Pharmacist.
Pharmaceutical Technology
MAY 31, 2023
Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome. Pharmanovia will hold exclusive rights for the commercialisation of elamipretide in the EU, other European countries including Switzerland, Norway, Iceland and the UK, and the Middle East and northern Africa region.
BioPharma Dive
MAY 31, 2023
The medicine, licensed from biotech ImmuNext in 2017, is one of two later-stage MS drug prospects in the French drugmaker’s portfolio.
Express Pharma
MAY 31, 2023
Glenmark Pharmaceuticals has joined the Science Based Targets initiative (SBTi) business ambition for well below 2°C. A company statement informed, “The SBTi’s has approved Glenmark’s commitment to reduce its absolute scope 1 and 2 GHG emissions by 35 per cent (from an FY2021 base year) by FY2035. The target boundary includes biogenic land‐related emissions and removals from bioenergy feedstock.
RX Note
MAY 31, 2023
Introduction In 2017, the Malaysian Diabetes Educators Society published the Forum for Injection Technique Malaysia (FIT-MY) to provide evidence-based injection technique recommendations for people with diabetes mellitus who use injectable therapy in their daily management. Proper subcutaneous administration of diabetes injectable medications requires careful consideration of factors such as The injection sites Needle length Use of a lifted skin fold Angle of injection NovoPen 3, NovoPen 4 and N
Outsourcing Pharma
MAY 31, 2023
A small molecule drug candidate from Algiax Pharmaceuticals can reduce excitability of neurons in relation to chronic pain, dampening signal and reducing pain, a study shows.
European Pharmaceutical Review
MAY 31, 2023
The novel CRISPR-Cas therapeutic selectively targets antibiotic-resistant E. coli which can cause life-threatening bloodstream infections” Positive interim results from a Phase I trial have demonstrated that the first CRISPR-armed phage microbial gene therapy can reduce Escherichia coli ( E. coli ) levels in the GI tract. “With the combined killing effects of bacteriophages and CRISPR-Cas technology, SNIPR001 has demonstrated the ability to target and eliminate antibiotic-resistant E
Pharma Times
MAY 31, 2023
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
World Pharma News
MAY 31, 2023
The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms.
pharmaphorum
MAY 31, 2023
ASCO 2023 preview: Prioritising the exploration of patient differences to enhance cancer care and research Mike.
Pharma Times
MAY 31, 2023
The neurological disease affects approximately 2.
Express Pharma
MAY 31, 2023
According to a recent study sponsored by Merck, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey. “Vaccine manufacturers in APAC are looking to build capacity for mRNA technology over the next two to three years, while continuing to produce both traditional and modern cell-based vaccines.
pharmaphorum
MAY 31, 2023
PM Society’s ‘Securing Market Access to Medicines for England, Ireland, Scotland & Wales’ – part one Mike.
Big Molecule Watch
MAY 31, 2023
Advanz Pharma (“Advanz”) and Alvotech announced that they entered an exclusive partnership agreement regarding supply and commercialization of five biosimilars in Europe, with Alvotech responsible for the development and commercial supply of the biosimilars, and Advanz responsible for registration and commercialization in Europe. Per the announcement, the agreement includes proposed biosimilars to SIMPONI® (golimumab) and ENTYVIO® (vedolizumab) and three undisclosed, early stage biosimilar cand
Pharmacy Joe
MAY 31, 2023
In this episode, I’ll discuss the dose of IV levothyroxine used for myxedema coma. Episode 822: How Much IV levothyroxine is Enough for Myxedema Coma? Subscribe on iTunes , Android , or Stitcher Myxedema coma is a rare medical emergency with in-hospital mortality of ~30% When it occurs, myxedema coma is often a result of either: 1. Withdrawal of thyroid therapy or 2.
FDA Law Blog: Biosimilars
MAY 31, 2023
By John A. Gilbert — CBS News caused a bit of commotion last week in reporting that after a four-year delay, DEA issued a final order revoking Morris & Dickson’s DEA registration. However, until today there had been no public information about this decision. This morning, the Federal Register published two DEA notices on the Morris & Dickson matter ( here and here ).
Pharmaceutical Technology
MAY 31, 2023
The University of Sydney and Australian company Pharos Therapeutics have reached an agreement to leverage artificial intelligence (AI) to progress drug discoveries for the treatment of cancer and rare diseases. The university and Pharos have drawn up a memorandum of understanding (MoU) to use AI technology to identify potential compounds for the rapid development of treatments.
pharmaphorum
MAY 31, 2023
Sanofi scores in MS with CD40 antibody frexalimab Phil.
Welltopia Pharmacy
MAY 31, 2023
Discover the wide range of medical applications of Methylene Blue, from treating methemoglobinemia to potential Alzheimer's disease treatments. Learn more in our comprehensive guide.
PharmaTech
MAY 31, 2023
When developing a tablet or capsule formulation, three widely used technologies are often considered to produce solid dosage forms: direct compression, wet granulation and dry granulation (including roller compaction). This article discusses why roller compaction is a robust option.
Pharmaceutical Technology
MAY 31, 2023
ZNA-1041 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZNA-1041’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
PharmaTech
MAY 31, 2023
Although probiotics are mostly administered in the form of capsules, there are some advantages of tablets in terms of production effort, cost efficiency and stability of the probiotic bacteria.
Expert insights. Personalized for you.
246 
Let's personalize your content